Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations

Boston, MA 09/16/2014 (wallstreetpr) – In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. (NASDAQ:GILD) authorized various drug companies in India. The actual price of hepatitis C pill of the company is $1,000-a-day, which will now be sold at just a dime in the […]

Gilead Sciences, Inc. (NASDAQ:GILD) Set To Hike Its New Hepatitis C Drug Price

Boston, MA 09/15/2014 (wallstreetpr) – Biopharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD) is set to lift the price of its next generation edition of hepatitis C drug. The company has already been facing pressures of higher costs from the insurers and the latest move meant that the treatment would be more expensive than ever before. To […]